Safety and efficacy of fingolimod in patients with multiple sclerosis in real world setting

Trial Profile

Safety and efficacy of fingolimod in patients with multiple sclerosis in real world setting

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Fingolimod (Primary) ; Natalizumab
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms VIRGILE
  • Most Recent Events

    • 02 Nov 2016 Results from one year data analysis (n=1011), presented at the 19th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 24 Feb 2016 Planned number of patients changed from 1200 to 1800.
    • 23 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top